Abstract-The intimal thickening that follows vascular injury is inhibited by periprocedural tissue factor pathway inhibitor (TFPI) treatment in animal models. TFPI is a multivalent Kunitz-type protease inhibitor that inhibits factor Xa via its second Kunitz domain and the factor VIIa/tissue factor (TF) complex via its first Kunitz domain. The basic C-terminus of TFPI is required for the binding of TFPI to cell surfaces and cell-bound TFPI mediates the internalization and degradation of factor X and the down regulation of surface factor VIIa/TF activity. The C-terminus of TFPI is also required for its reported direct inhibition of smooth muscle cell proliferation in vitro. To examine the structural requirements for the inhibition of neointimal formation by TFPI, several TFPI-related proteins were tested in the rat carotid angioplasty model: 1) XK 1 , a hybrid protein containing the N-terminal portion of factor X and the first Kunitz domain of TFPI that directly inhibits factor VIIa/TF; 2) TFPI WT , the full-length TFPI molecule that inhibits factor Xa and factor VIIa/TF and binds cell surfaces; 3) TFPI K36I , an altered form of TFPI that inhibits factor Xa, but not factor VIIa/TF, and binds cell surfaces; 4) TFPI 13-161 , a truncated form of TFPI that inhibits factor VIIa/TF but interacts with factor Xa poorly and does not bind to cell surfaces. Seven day infusions of XK 1 , TFPI WT , and high levels of TFPI K36I begun the day before balloon-induced vascular injury produced a significant reduction in the intimal hyperplasia measured 28 days after angioplasty. The infusion of high concentrations of TFPI was ineffective in this model. These in vivo results directly mirror the ability of each TFPI-related protein to inhibit tissue thromboplastin-induced coagulation in rat plasma: XK 1 ϷTFPI WT ϾTFPI K36I Ͼ ϾTFPI . The studies confirm the important role of TF-mediated coagulation in the smooth muscle proliferation and neointimal thickening that follows vascular injury and suggest that the anticoagulant effect alone of TFPI and TFPI-related proteins is sufficient to explain their therapeutic action. Key Words: tissue factor pathway inhibitor Ⅲ angioplasty Ⅲ rat T he mechanisms underlying the intimal thickening and associated restenosis that follow arterial injury are complex, but recent data suggest that activation of the coagulation cascade plays an important role in the process. 1-6 Tissue factor (TF) is an integral membrane protein that serves as an essential cofactor for plasma factor VII(a) in the initiation of coagulation. TF is present at high levels in atherosclerotic plaques, and TF expression is induced in vascular smooth muscle cells after balloon injury. [7] [8] [9] The factor VIIa/TF catalytic complex activates factor X, which in turn produces thrombin generation. Both factor Xa and thrombin have been shown to be potent mitogens for vascular smooth cells in vitro. 4 -6 Moreover, anticoagulant agents that inhibit thrombin (hirudin), factor Xa (tick anticoagulant protein, TAP), or factor VIIa/TF (inactivated factor VIIa [VIIai], tissue factor pathway inhibitor [TFPI]) reduce postangioplasty intimal hyperplasia in animal models. 10 -14 TFPI is a trivalent Kunitz-type proteinase inhibitor, which circulates at trace concentrations (Ϸ2 nmol/L) in human plasma. The in vivo infusion of heparin and other polyanions increases the circulating levels of TFPI in plasma 2-to 4-fold, and the source of this additional TFPI is thought to be the endothelium. TFPI directly inhibits factor Xa and, at physiological concentrations, produces factor Xa-dependent inhibition of the factor VIIa/TF complex. The TFPI molecule contains an acidic aminoterminal region followed by three tandem Kunitz-type domains and a basic carboxy-terminal region. The second Kunitz-domain of TFPI is responsible for factor Xa inhibition, but other parts of the molecule are involved in its interaction with factor Xa. The basic carboxy-terminal region of TFPI is required for rapid inhibition of factor Xa and the enhancement of TFPI-mediated factor Xa inhibition produced by heparin and other polyanions. Factor Xa-dependent inhibition of the factor VIIa/TF complex by TFPI involves the formation of a quaternary complex containing factor Xa-TFPI-factor VIIa/TF in which the second Kunitz domain of TFPI binds factor Xa and the first Kunitz domain binds factor VIIa. The requirement of factor Xa for the inhibition of factor VIIa/TF by TFPI is not absolute, and at high, therapeutic concentrations TFPI inhibits the factor VIIa/TF catalytic complex in the absence of factor Xa. [15] [16] [17] [18] [19] [20] 
T he mechanisms underlying the intimal thickening and associated restenosis that follow arterial injury are complex, but recent data suggest that activation of the coagulation cascade plays an important role in the process. [1] [2] [3] [4] [5] [6] Tissue factor (TF) is an integral membrane protein that serves as an essential cofactor for plasma factor VII(a) in the initiation of coagulation. TF is present at high levels in atherosclerotic plaques, and TF expression is induced in vascular smooth muscle cells after balloon injury. [7] [8] [9] The factor VIIa/TF catalytic complex activates factor X, which in turn produces thrombin generation. Both factor Xa and thrombin have been shown to be potent mitogens for vascular smooth cells in vitro. 4 -6 Moreover, anticoagulant agents that inhibit thrombin (hirudin), factor Xa (tick anticoagulant protein, TAP), or factor VIIa/TF (inactivated factor VIIa [VIIai] , tissue factor pathway inhibitor [TFPI] ) reduce postangioplasty intimal hyperplasia in animal models. 10 -14 TFPI is a trivalent Kunitz-type proteinase inhibitor, which circulates at trace concentrations (Ϸ2 nmol/L) in human plasma. The in vivo infusion of heparin and other polyanions increases the circulating levels of TFPI in plasma 2-to 4-fold, and the source of this additional TFPI is thought to be the endothelium. TFPI directly inhibits factor Xa and, at physiological concentrations, produces factor Xa-dependent inhibition of the factor VIIa/TF complex. The TFPI molecule contains an acidic aminoterminal region followed by three tandem Kunitz-type domains and a basic carboxy-terminal region. The second Kunitz-domain of TFPI is responsible for factor Xa inhibition, but other parts of the molecule are involved in its interaction with factor Xa. The basic carboxy-terminal region of TFPI is required for rapid inhibition of factor Xa and the enhancement of TFPI-mediated factor Xa inhibition produced by heparin and other polyanions. Factor Xa-dependent inhibition of the factor VIIa/TF complex by TFPI involves the formation of a quaternary complex containing factor Xa-TFPI-factor VIIa/TF in which the second Kunitz domain of TFPI binds factor Xa and the first Kunitz domain binds factor VIIa. The requirement of factor Xa for the inhibition of factor VIIa/TF by TFPI is not absolute, and at high, therapeutic concentrations TFPI inhibits the factor VIIa/TF catalytic complex in the absence of factor Xa. [15] [16] [17] [18] [19] [20] Besides its direct anticoagulant effects on factor Xa and factor VIIa/TF, TFPI possesses additional properties that may be related to its in vivo action. TFPI binds to the surface of cells through a process that requires its basic carboxyterminus and this cell-bound TFPI dramatically enhances the cellular binding, internalization, and degradation of factor Xa. 21 Moreover, in a process that involves a glycosylphosphatidyl-inositol-linked membrane protein that may represent the cell surface binder for TFPI, quaternary factor Xa-TFPI-factor VIIa/TF complexes are translocated to caveolae, thereby decreasing cell surface TF. 22, 23 In addition, TFPI reportedly inhibits TF-induced aortic smooth muscle cell migration 24 and neonatal aortic smooth muscle cell proliferation. 25 Whether these cellular effects of TFPI contribute to its in vivo action is not known.
Because recent studies have shown that recombinant, full-length TFPI reduces intimal thickening after vascular injury in the rabbit atherosclerotic femoral artery 11 and the carotid artery of the cholesterol-fed minipig, 10 we conducted the present study to evaluate the structures within the TFPI molecule that are important for its effect on neointimal formation. Accordingly, we tested a number of TFPI congeners in the rat carotid model of vascular injury.
Materials and Methods

Proteins
Human recombinant (r)TFPI WT , rTFPI K36I , and rTFPI were expressed in Escherichia coli and refolded in vitro as previously described. 26 rXK 1 was expressed in baby hamster kidney cells and isolated as previously described. 27 Each of the proteins appeared Ͼ90% pure by sodium dodecyl sulfate polyacrylamide gel electrophoresis. Due to limitations in their solubility, TFPI WT (4.7 mg/mL) and TFPI K36I (6 mg/mL) were reconstituted in 0.3 mol/L arginineHCl, 20 mmol/L sodium phosphate, pH 7.4 (arg-phos buffer). TFPI (28 mg/mL) and XK 1 (3 mg/mL) were reconstituted in 0.1 mol/L NaCl, 0.05 mol/L sodium phosphate, pH 7.4 (phosphatebuffered saline [PBS] buffer).
Delivery of TFPI Forms
Osmotic pumps with 2-mL capacity and a delivery rate of 10 uL/h (2 ML1, Alza Corp) were used to infuse the test reagents intravenously for 1 week. Following the manufacturer's instructions, pumps were loaded with protein solution or buffer controls and incubated at 37°C for 6 hours before implantation into anesthetized (ketamine 75 mg/kg, xylazine 10 mg/kg, acepromazine 5 mg/kg, IP) 300 to 350 g female Sprague-Dawley rats. A ventral incision was made in the neck and the left external jugular vein freed using blunt dissection. The rostral end of the vein was ligated and a PE60 polyethylene catheter (Becton Dickinson) connected to the osmotic pump was inserted proximally. The pump was placed in a subcutaneous pocket fashioned under the skin of the dorsal neck. To double the infusion rate of TFPI K36I in some of the rats, an additional pump was connected to the right jugular vein in the same fashion. The ventral incision was then closed with clips. Pumps were explanted 1 week after implantation. All protocols involving animals were approved by the Animal Studies Committee at Washington University.
Balloon-Induced Vascular Injury
Balloon injury of the left common carotid artery was produced the day after pump implantation. Rats were anesthetized as described above, the ventral incision opened, and the left external carotid artery identified. A 2 French balloon embolectomy catheter (Baxter) was introduced via the external carotid artery and advanced to the aorta. The balloon was partially inflated and the catheter withdrawn along the full length of the common carotid artery and then deflated. This procedure was repeated 3 times before the catheter was removed, the external carotid artery ligated, and the ventral neck incision closed.
Four weeks later, the animals were exsanguinated by perfusion through the heart with PBS followed by 4% formaldehyde. The left carotid artery was harvested (Ϸ2.5 cm) and immersion-fixed in 4% formaldehyde solution for histological examination.
Histologic Examination of Carotid Arteries
Fixed tissue was dehydrated and paraffin embedded according to standard protocols. The entire length of the carotid artery was step sectioned (100 m) and tissue sections stained with Verhoff's Van Gieson stain. Twenty consecutive sections around the greatest extent of neointimal thickening were selected for morphometric analysis using the ImagePro system (Media Cybernetics). The neointimal cross-sectional area was calculated by subtracting the cross-sectional area of the lumen from that demarcated by the internal elastic lamina. The area of the media was determined by subtracting the area inside the internal elastic membrane from that delineated by the external elastic membrane. The ratio of the intimal area to the medial area was calculated for each of 20 sections, and an average ratio was determined for each carotid. Statistical analysis was done with unpaired Student's t test to evaluate 2-tailed levels of significance between treated group and control group, respectively.
Immunoassay of TFPI Forms
Blood was drawn from the retroorbital sinus of the rats into ethylenediamine-tetraacetic acid-coated capillary tubes at the time of angioplasty, and plasma was obtained by centrifugation. For assay, test plasma or normal rat plasma containing various concentrations of the specific TFPI-related protein were diluted 5-fold into 0.1 mol/L NaCl, 0.05 mol/L Tris-HCl, pH 7.4 containing 1 mg/mL bovine serum albumin. To determine levels of TFPI WT , TFPI K36I and TFPI , 20 uL of diluted sample or standard was added to 20 uL 0.5% (wt/vol) latex beads coated with the monoclonal anti-TFPI antibody MC2B12 (100 g/mL), which recognizes the second Kunitz domain of TFPI, in a well of a Fluorocon microtiter plate (Baxter). In the case of XK 1 , 20 uL of diluted plasma sample or standard was added to 20 uL 0.5% (wt/vol) latex beads coated with the monoclonal antifactor X antibody MC1066 (100 g/mL), which recognizes the light chain of factor X. After the addition of 20 uL fluorescein isothiocyanate-labeled monoclonal anti-TFPI antibody MC2H8, which recognizes the first Kunitz domain of TFPI, the mixtures were incubated for 30 minutes at room temperature before the beads were washed and the latex bead associated fluorescein isothiocyanate determined using a Fluorescence Concentration Analyzer (Baxter).
Factor VIIa/TF Activity Inhibition
The relative ability of TFPI WT , TFPI K36I , and TFPI to inhibit factor VIIa/TF in the presence of factor Xa was determined using a commercially available kit (Actichrome TFPI, American Diagnostica Inc). This is an end-point assay in which factor VIIa, tissue factor, a small quantity of factor X(a), and the inhibitor are first incubated for 30 minutes. Factor X is then added, and the extent of factor Xa generated in 15 minutes by the remaining factor VIIa/TF activity determined by the addition of ethylenediamine-tetraacetic acid (to stop the reaction) and the chromogenic substrate Spectrazyme Xa (American Diagnostica, Inc).
Anticoagulant Activity of TFPI Forms
The TFPI forms were tested for their ability to inhibit the coagulation of rat plasma induced by tissue factor (rat brain thromboplastin) and the factor X-coagulant protein (XCP) of Russells Viper venom, which directly activates factor X.
Rat Thromboplastin-Induced Coagulation
Rat thromboplastin was prepared as a crude saline extract of rat brain (Pel Freez Biologicals) as previously described. 28 In a fibrometer (BBL), 50 uL of rabbit brain cephalin (1:8 dilution of stock suspension, Sigma), 50 uL of CaCl 2 (50 mmol/L), 50 uL rat thromboplastin (1:5 dilution), and 50 uL of various concentrations of test inhibitor are incubated at 37°C. After 30 seconds, 50 uL normal rat plasma (Pel Freez) is added and the time of clot formation determined. Apparent inhibition of thromboplastin-induced coagula-tion is determined by comparison of clotting times with a standard curve constructed using various concentrations of thromboplastin.
XCP-Induced Coagulation
In a fibrometer, 60 uL CaCl 2 (50 mmol/L), 60 uL XCP (45 pM) in rabbit brain cephalin (1:8 dilution), and 60 uL of various concentrations of test inhibitor are incubated at 37°C. After 30 seconds, 60 uL of normal rat plasma is added and the time to clot formation determined. Apparent inhibition of XCP-induced coagulation is determined by comparison of clotting times with a standard curve constructed using various concentrations of XCP.
Results
Characterization of TFPI-Related Molecules
Four TFPI-related molecules were evaluated: TFPI WT , TFPI K36I , TFPI , and XK 1 . TFPI WT is the native full-length molecule that inhibits factor Xa, factor VIIa/TF, and binds to cell surfaces. In TFPI K36I , the P 1 residue at the inhibitory cleft within the first Kunitz domain of TFPI has been changed from a lysine to an isoleucine. This molecule does not inhibit factor VIIa/tissue factor (Figure 1 ) but retains the ability to inhibit factor Xa and bind to cells. TFPI is a truncated form of TFPI that lacks the third Kunitz domain and the remainder of the carboxy-terminus of the native molecule. TFPI inhibits factor Xa, albeit much less avidly than TFPI WT , 16 and inhibits the factor VIIa/TF complex (Figure 1 ). Lacking the carboxy-terminal basic region of TFPI, TFPI does not bind to cell surfaces. Finally, XK 1 is a chimeric protein that contains the amino-terminal light-chain of factor X linked to the first Kunitz domain of TFPI. XK 1 directly inhibits factor VIIa/TF 27 but does not inhibit factor Xa.
The relative anticoagulant activities of the TFPI forms in rat plasma were tested in 1-stage coagulation assays in which coagulation was induced by the factor X-coagulant protein (XCP) from Russells Viper venom or rat brain thromboplastin ( 
Effect of TFPI-Forms on Intimal Thickening After Vascular Injury
The relative efficacy of the various forms of TFPI in the inhibition of intimal thickening after vascular injury was tested in the rat carotid balloon injury model. 29 Representative histological sections of carotid arteries obtained 28 days after injury from each treatment group are shown in Figure 2 .
The degree of neointimal thickening was assessed by calculating the ratio of intima area:media area within the injured artery (Table 2 ). In the animals treated with TFPI WT and XK 1 , there was significant reduction of neointimal formation compared with all other treated groups and the buffer controls (PϽ0.01 to Ͻ0.001). TFPI K36I at a high infusion rate also produced a significant reduction of the intima:media ratio compared with buffer control, whereas TFPI 13-161 treatment did not significantly effect the extent of neointimal thickening after vascular injury. Hemorrhagic complications were not observed in the treated animals.
Discussion
A 24-hour infusion of TFPI has been shown previously to reduce neointimal thickening after balloon vascular injury in the cholesterol-fed pig, 10 whereas a 3-day infusion of rTFPI was effective in decreasing neointimal thickening after airdesiccation injury in cholesterol-fed rabbits. 11 TFPI has multiple functional attributes, including the inhibition of factor Xa, the inhibition of factor VIIa/TF, and cellular effects related to its ability to bind to cell surfaces. 18 -25 To examine the structural determinants and mechanism(s) of the therapeutic efficacy of TFPI, we tested a variety of TFPI-related agents for their ability to inhibit neointimal thickening after balloon overstretch injury of the rat carotid artery.
The relative efficacy of the TFPI-related agents in reducing neointimal thickening mirrored their relative anticoagulant potency in a 1-stage plasma assay of thromboplastin-induced coagulation: XK 1 ϳTFPI WT ϾTFPI K36I Ͼ ϾTFPI (Tables 1  and 2 ). These results are consistent with previous data suggesting an important role for tissue factor-induced coagulation in the formation of neointima after vascular injury in rabbits and pigs, 10, 11 and they occurred despite the lack of marked thrombus formation in the rat vascular injury preparation. Moreover, the results suggest that the anticoagulant 
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properties of these TFPI-related agents alone can explain their therapeutic benefit. Of the 2 most potent agents, XK 1 reduces factor Xa generation by directly inhibiting the factor VIIa/TF complex, whereas TFPI WT not only inhibits factor Xa generation by factor VIIa/TF but also inhibits factor Xa itself. Plasma concentrations achieved during the constant intravenous infusion of these agents were several-fold higher than their IC 50 's for inhibition of tissue thromboplastin-induced coagulation (Tables 1 and 2). TFPI K36I , which does not inhibit factor VIIa/tissue factor but is a potent inhibitor of factor Xa, was less effective than either XK 1 or TFPI WT in inhibiting neointimal thickening (Table 2 ). However, even at the "high" dosage level, the plasma concentration of TFPI K36I achieved during constant infusion (Ϸ13 nmol/L) was lower than its IC 50 (16 nmol/L) for inhibition of tissue thromboplastin-induced coagulation (Table 1) . We interpret the apparent dose response found with TFPI K36I to imply that higher levels of TFPI K36I (Ͼ ϾIC 50 ) may have been more effective, yielding effects on neointimal thickening similar to XK 1 and TFPI WT . In contrast, although the factor VIIa/tissue factor inhibition produced by TFPI in an endpoint assay was comparable with that of TFPI WT (Figure 1) , this agent was a poor anticoagulant and failed to inhibit neointimal thickening (Tables 1 and 2) .
Interestingly, although the anticoagulant effect of TFPI K36I was equivalent to that of TFPI WT in the XCP assay, TFPI K36I was 4-fold less active than TFPI WT in the tissue thromboplastin assay (Table 1 ). This result suggests that a significant proportion of the anticoagulant effect of TFPI WT in a 1-stage assay of tissue thromboplastin-induced coagulation is due to its inhibition of factor VIIa/TF or, alternatively, that the TFPI-mediated inhibition of the initial factor Xa generated by the factor VIIa/TF complex is enhanced when the TFPI is able to bind simultaneously to factor Xa and factor VIIa in a factor VIIa/TF-factor Xa tertiary complex. 30 Preliminary experiments indicate that the latter explanation is more likely (Han and Broze, unpublished observations, 1998).
That an effect of TFPI related to cell-surface binding contributes to its beneficial effect after vascular injury cannot be excluded. Nevertheless, like hirudin, TAP, and VIIai, the anticoagulant actions of the TFPI-related proteins were sufficient to predict their ability to inhibit neointimal formation. The treatment of choice for this indication will likely depend on the incidence of hemorrhagic complications. Recent studies have suggested that agents targeting factor VIIa/TF (eg, VIIai, anti-TF antibodies) may induce less bleeding than agents that target coagulation at latter stages. [31] [32] [33] Consistent with this notion, in preliminary studies, plasma levels of XK 1 Ͼ100-fold its IC 50 in the rat thromboplastin-induced coagulation assay did not produce hemorrhagic manifestations during the surgical manipulations required for the balloon angioplasty procedure.
